The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).
 
Rongbo Lin
No Relationships to Disclose
 
Ye Zaisheng
No Relationships to Disclose
 
Zhuo Changhua
No Relationships to Disclose
 
Shenghong - Wei
No Relationships to Disclose
 
Zhixiong Li
No Relationships to Disclose
 
Shen Zhao
No Relationships to Disclose
 
Liyu Su
No Relationships to Disclose